Allergan: anti migrane treatment obtains FDA approval
(CercleFinance.com) - On Monday at the end of trading, Allergan announced it had received FDA approval for Ubrelvy (ubrogepant) for the acute treatment of migrane with or without aura in adults, affecting 31 million sufferers in the U.
S.
In clinical trials backing up the FDA approval, Ubrelvy was shown to provide rapid pain relief for the majority of migrane sufferers, the Dublin-based pharmaceutical group underlined.
Ubrelvy also reached its co-primary endpoints of freedom from pain and freedom from the most bothersome symptom (nausea, hypersensitivity to light, or hypersensitivity to sound), a recent, more stringent standard of efficacy the FDA set in 2018.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
S.
In clinical trials backing up the FDA approval, Ubrelvy was shown to provide rapid pain relief for the majority of migrane sufferers, the Dublin-based pharmaceutical group underlined.
Ubrelvy also reached its co-primary endpoints of freedom from pain and freedom from the most bothersome symptom (nausea, hypersensitivity to light, or hypersensitivity to sound), a recent, more stringent standard of efficacy the FDA set in 2018.
Copyright (c) 2019 CercleFinance.com. All rights reserved.